Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 1031 to 1040 of 1090 total matches.
Atovaquone for Pneumocystis Carinii Pneumonia
The Medical Letter on Drugs and Therapeutics • Apr 02, 1993 (Issue 893)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Atovaquone (Mepron - Burroughs Wellcome), a hydroxynaphthoquinone, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of mild to moderate Pneumocystis carinii pneumonia (PCP) in patients who cannot tolerate trimethoprim-sulfamethoxazole (Septra, Bactrim, and others). PCP is a common opportunistic infection and frequent cause of death in patients with AIDS.
SAMe For Depression
The Medical Letter on Drugs and Therapeutics • Nov 05, 1999 (Issue 1065)
Psychiatry, 147:591, 1990).
No adverse interactions between SAMe and any other drug have been reported ...
S-adenosyl-methionine (SAM; SAMe; ademetionine; adomet), an endogenous compound synthesized from methionine and adenosine-triphosphate (ATP), has been marketed in stores and on the internet as a dietary supplement to promote "emotional well being."
Altretamine For Ovarian Cancer
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991 (Issue 850)
with altretamine Interactions drug Hexastat Hexamethylmelamine Hexalen ...
Altretamine (Hexalen - US Bioscience; Hexastat - Rh ne-Poulenc in Canada), formerly known only by its chemical name, hexamethylmelamine, was recently approved by the US Food and Drug Administration as a single agent for palliative oral treatment of persistent or recurrent ovarian cancer.
Quinapril for Hypertension
The Medical Letter on Drugs and Therapeutics • Mar 20, 1992 (Issue 866)
Potassium Monopril Interactions drug with quinapril lisinopril lithium Lotensin Midamor ...
Quinapril (Accupril - Parke-Davis), an angiotensin-converting enzyme (ACE) inhibitor, has been approved by the US Food and Drug Administration (FDA) for treatment of hypertension. ACE inhibitors are now widely used for this indication (Medical Letter, 33:33, 1991).
Liptruzet: A Combination of Ezetimibe and Atorvastatin
The Medical Letter on Drugs and Therapeutics • Jun 24, 2013 (Issue 1419)
with simvastatin.6 Atorvastatin, which has fewer
interactions with other drugs, may be safer.
CONCLUSION ...
The FDA has approved a fixed-dose combination of
the cholesterol absorption inhibitor ezetimibe and the
HMG-CoA reductase inhibitor (statin) atorvastatin as
Liptruzet (Merck) for treatment of hyperlipidemia.
Ezetimibe is also available in a fixed-dose combination
with simvastatin (Vytorin).
Comparison Table: Some Antibiotics for MRSA Skin and Skin Structure Infections (online only)
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
in vitro; may be less
likely than linezolid to interact with serotonergic drugs
1660.604
Comparison ...
View the Comparison Table: Some Antibiotics for MRSA Skin and Skin Structure Infections
Bimekizumab (Bimzelx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
expensive
than other oral drugs, but it increases the risk of
infection and can cause serious hematologic ...
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx
– UCB) for treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic
treatment or phototherapy. Bimekizumab is the first
IL-17A/17F antagonist to be approved in the US. It
was approved in the European Union for the same
indication in 2021.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):11-3 doi:10.58347/tml.2024.1694b | Show Introduction Hide Introduction
Atezolizumab (Tecentriq) for Alveolar Soft Part Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
). Atezolizumab is
the first drug to be approved in the US for treatment
of ASPS. ASPS is a rare disorder ...
Atezolizumab (Tecentriq – Genentech), an immune
checkpoint inhibitor, has been approved by the FDA
for treatment of unresectable or metastatic alveolar
soft part sarcoma (ASPS) in patients ≥2 years old. It
was previously approved for treatment of non-small
cell lung cancer, small cell lung cancer, hepatocellular
cancer, and melanoma (see Table 1). Atezolizumab is
the first drug to be approved in the US for treatment
of ASPS. ASPS is a rare disorder that affects mostly
adolescents and young adults; <1% of soft tissue
sarcomas are ASPS.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e56-7 doi:10.58347/tml.2023.1673d | Show Introduction Hide Introduction
Cemiplimab (Libtayo) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
to biologic drugs to distinguish
reference products from their biosimilars.
meeting predetermined overall ...
The FDA has approved cemiplimab-rwlc (Libtayo –
Regeneron), an immune checkpoint inhibitor, for use in
combination with platinum-based chemotherapy for
first-line treatment of locally advanced or metastatic
non-small cell lung cancer (NSCLC) in adults with no
epidermal growth factor receptor (EGFR), anaplastic
lymphoma kinase (ALK), or ROS1 aberrations and
who are not candidates for surgical resection or
chemoradiation. The drug was previously approved
for first-line treatment of NSCLC in patients whose
tumors have high PD-L1 expression and no genomic
tumor aberrations....
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e67-8 doi:10.58347/tml.2023.1674e | Show Introduction Hide Introduction
Tiludronate for Paget's Disease of Bone
The Medical Letter on Drugs and Therapeutics • Jul 18, 1997 (Issue 1005)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Tiludronate (Skelid - Sanofi), a chloro-4-phenylthiomethylene bisphosphonate, has been approved by the US Food and Drug Administration (FDA) for treatment of Paget's disease of bone. Characterized by excessive bone resorption and disorganized bone remodeling, Paget's disease occurs in up to 3% of people more than 55 years old in Europe and North America (PD Delmas and PJ Meunier, N Engl J Med, 336:558, Feb 20, 1997).